Idiopathic pulmonary fibrosis (IPF) is a devastating and progressive lung disease. Its aetiology is thought to involve damage to the epithelium and abnormal repair. Alveolar epithelial cells near areas of remodelling show an increased expression of proapoptotic molecules. Therefore, we investigated the role of genes involved in cell cycle control in IPF. Genotypes for five single nucleotide polymorphisms (SNPs) in the tumour protein 53 (TP53) gene and four SNPs in cyclin-dependent kinase inhibitor 1A (CDKN1A), the gene encoding p21, were determined in 77 IPF patients and 353 controls. In peripheral blood mononuclear cells (PBMC) from 16 healthy controls mRNA expression of TP53 and CDKN1A was determined. Rs12951053 and rs12602273, in TP53, were significantly associated with survival in IPF patients. Carriers of a minor allele had a 4-year survival of 22% versus 57% in the non-carrier group (p = 0.006). Rs2395655 and rs733590, in CDKN1A, were associated with an increased risk of developing IPF. In addition, the rs2395655 G allele correlated with progression of the disease as it increased the risk of a rapid decline in lung function. Functional experiments showed that rs733590 correlated significantly with CDKN1A mRNA expression levels in healthy controls. This is the first study to show that genetic variations in the cell cycle genes encoding p53 and p21 are associated with IPF disease development and progression. These findings support the idea that cell cycle control plays a role in the pathology of IPF. Variations in TP53 and CDKN1A can impair the response to cell damage and increase the loss of alveolar epithelial cells.
References
[1]
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174: 810–816.
[2]
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, et al. (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61: 980–985.
[3]
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, et al. (2011) The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66: 462–467.
[4]
Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, et al. (1998) Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 53: 469–476.
[5]
Rudd RM, Prescott RJ, Chalmers JC, Johnston ID (2007) British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival. Thorax 62: 62–66.
[6]
(2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2): 277–304.
[7]
Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, et al. (2003) Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168: 538–542.
[8]
Hanson D, Winterbauer RH, Kirtland SH, Wu R (1995) Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108: 305–310.
[9]
van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, et al. (2010) Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med 182: 1419–1425.
[10]
Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, et al. (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364: 1503–1512.
[11]
Grutters JC, du Bois RM (2005) Genetics of fibrosing lung diseases. Eur Respir J 25: 915–927.
[12]
Vancheri C, Failla M, Crimi N, Raghu G (2010) Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 35: 496–504.
[13]
Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, et al. (2005) Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127: 266–274.
[14]
Canman CE, Kastan MB (1997) Role of p53 in apoptosis. Adv Pharmacol 41: 429–460.
[15]
Kastan MB (1993) P53: a determinant of the cell cycle response to DNA damage. Adv Exp Med Biol 339: 291–293.
[16]
Krtolica A, Campisi J (2002) Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 34: 1401–1414.
[17]
Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639–649.
[18]
Verleden GM, du Bois RM, Bouros D, Drent M, Millar A, et al. (2001) Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J Suppl 3217s–29s.
[19]
Egan JJ, Martinez FJ, Wells AU, Williams T (2005) Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 60: 270–273.
[20]
de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217–1223.
[21]
Choi YY, Kang HK, Choi JE, Jang JS, Kim EJ, et al. (2008) Comprehensive assessment of P21 polymorphisms and lung cancer risk. J Hum Genet 53: 87–95.
[22]
George Priya Doss C, Sudandiradoss C, Rajasekaran R, Choudhury P, Sinha P, et al. (2008) Applications of computational algorithm tools to identify functional SNPs. Funct Integr Genomics 8: 309–316.
[23]
Heron M, Grutters JC, van Moorsel CH, Ruven HJ, Kazemier KM, et al. (2009) Effect of variation in ITGAE on risk of sarcoidosis, CD103 expression, and chest radiography. Clin Immunol 133: 117–125.
[24]
Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95: 221–227.
[25]
King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, et al. (2005) Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 127: 171–177.
[26]
Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA (1997) Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155: 242–248.
[27]
Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, et al. (2010) Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181: 254–263.
[28]
Warburton D, Perin L, Defilippo R, Bellusci S, Shi W, et al. (2008) Stem/progenitor cells in lung development, injury repair, and regeneration. Proc Am Thorac Soc 5: 703–706.
[29]
Nakashima N, Kuwano K, Maeyama T, Hagimoto N, Yoshimi M, et al. (2005) The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. J Clin Pathol 58: 583–589.
[30]
Bhaskaran M, Kolliputi N, Wang Y, Gou D, Chintagari NR, et al. (2007) Trans-differentiation of alveolar epithelial type II cells to type I cells involves autocrine signaling by transforming growth factor beta 1 through the Smad pathway. J Biol Chem 282: 3968–3976.
[31]
Inoshima I, Kuwano K, Hamada N, Yoshimi M, Maeyama T, et al. (2004) Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 286: L727–L733.
[32]
Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, et al. (2009) p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 106(45): 19035–9.
[33]
Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.
[34]
Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K (2002) Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121: 1278–1289.
